Immunology of hepatocellular carcinoma

World Journal of Hepatology

Volumn 7, Issue 17, 2015, Pages 2080-2090

  Sachdeva, Meenakshi ^a   Chawla, Yogesh K ^a   Arora, Sunil K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Adaptive immunity; Hepatocellular carcinoma; Immune cells; Immune dysregulation; Innate immunity

Indexed keywords

EID: 84939211225     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i17.2080     Document Type: Review

References (89)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]
2. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42 Suppl 3: S206-S214 [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5]
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134:1752-1763 [PMID: 18471552 DOI: 10.1053/j.gastro.2008.02.090]
4. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063 [PMID:19003900 DOI: 10.1002/hep.22580]
5. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 2004; 11: 383-393 [PMID: 15357643 DOI: 10.1111/j.1365-2893.2004.00521.x]
6. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208 [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052]
7. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832 [PMID: 20432259 DOI: 10.1002/hep.23594]
8. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899 [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025]
9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570 [PMID: 21436444 DOI: 10.1126/science.1203486]
10. Aravalli RN. Role of innate immunity in the development of hepatocellular carcinoma. World J Gastroenterol 2013; 19:7500-7514 [PMID: 24282342 DOI: 10.3748/wjg.v19.i43.7500]
11. Matsui M, Machida S, Itani-Yohda T, Akatsuka T. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferongamma. J Gastroenterol Hepatol 2002; 17: 897-907 [PMID: 12164966]
12. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999; 31: 323-331 [PMID: 10453947]
13. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-350 [PMID: 9670046]
14. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, Yoshioka K. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 2000; 15: 431-436 [PMID: 10824889]
15. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, Michitaka K, Horiike N, Onji M. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 2000; 148: 49-57 [PMID: 10680592]
16. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y, Lin C, Pan Z, Yu Y, Jiang M, Zhou W, Cao X. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T- cell response by cytotoxic T- lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 2014; 59:567-579 [PMID: 23960017 DOI: 10.1002/hep.26694]
17. Solinas G, Germano G, Mantovani A, Allavena P. Tumorassociated macrophages (TAM) as major players of the cancerrelated inflammation. J Leukoc Biol 2009; 86: 1065-1073 [PMID:19741157 DOI: 10.1189/jlb.0609385]
18. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896 [PMID: 20856220 DOI: 10.1038/ni.1937]
19. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumorassociated macrophages. Biomed Res Int 2013; 2013: 187204 [PMID: 23533994 DOI: 10.1155/2013/187204]
20. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008; 26: 2707-2716 [PMID: 18509183 DOI: 10.1200/JCO.2007.15.6521]
21. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111 [PMID:16904609 DOI: 10.1016/j.ccr.2006.06.016]
22. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-174 [PMID: 19197294 DOI: 10.1038/nri2506]
23. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135:234-243 [PMID: 18485901 DOI: 10.1053/j. gastro.2008.03.020]
24. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54: 948-955 [PMID: 21145847 DOI: 10.1016/j.jhep.2010.08.041]
25. Subleski JJ, Wiltrout RH, Weiss JM. Application of tissuespecific NK and NKT cell activity for tumor immunotherapy. J Autoimmun 2009; 33: 275-281 [PMID: 19682859 DOI: 10.1016/j.jaut.2009.07.010]
26. Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology 2013; 57: 1654-1662 [PMID: 23111952 DOI: 10.1002/hep.26115]
27. Vermijlen D, Luo D, Froelich CJ, Medema JP, Kummer JA, Willems E, Braet F, Wisse E. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol 2002; 72: 668-676 [PMID: 12377935]
28. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009; 86: 513-528 [PMID: 19542050 DOI: 10.1189/JLB.0309135]
29. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, Zhang H, Yang Y, Wu H, Tien P, Wang FS. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129:428-437 [PMID: 18824414 DOI: 10.1016/j.clim.2008.08.012]
30. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012; 56: 769-775 [PMID:22378017 DOI: 10.1002/hep.25670]
31. Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R. Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology 2008; 48: 963-977 [PMID: 18726940 DOI: 10.1002/hep.22413]
32. Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis 2011; 32:1434-1440 [PMID: 21771728 DOI: 10.1093/carcin/bgr133]
33. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010; 207: 1791-1804 [PMID: 20660615 DOI: 10.1084/jem.20092454]
34. Attallah AM, Tabll AA, El-Sadany M, Ibrahim TA, El-Dosoky I. Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma. Clin Exp Med 2003; 3: 181-185 [PMID: 14648234 DOI: 10.1007/s10238-003-0023-y]
35. Murakami S. Soluble interleukin-2 receptor in cancer. Front Biosci 2004; 9: 3085-3090 [PMID: 15353339]
36. Cabrera R, Ararat M, Cao M, Xu Y, Wasserfall C, Atkinson MA, Liu C, Nelson DR. Hepatocellular carcinoma immunopathogenesis:clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci 2010; 55: 484-495 [PMID: 19714465 DOI: 10.1007/s10620-009-0955-5]
37. Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009; 69: 8067-8075 [PMID: 19826049 DOI: 10.1158/0008-5472. CAN-09-0901]
38. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206: 1327-1337 [PMID: 19451266 DOI: 10.1084/jem.20082173]
39. Ma CS, Suryani S, Avery DT, Chan A, Nanan R, Santner-Nanan B, Deenick EK, Tangye SG. Early commitment of naïve human CD4(+) T cells to the T follicular helper (T(FH)) cell lineage is induced by IL-12. Immunol Cell Biol 2009; 87: 590-600 [PMID:19721453 DOI: 10.1038/icb.2009.64]
40. Wang XD, Wang L, Ji FJ, Zhu JM, Ayana DA, Fang XD. Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma. J Int Med Res 2012; 40: 307-316 [PMID: 22429370]
41. Jia Y, Zeng Z, Li Y, Li Z, Jin L, Zhang Z, Wang L, Wang FS. Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression. PLoS One 2015; 10: e0117458 [PMID: 25689070 DOI: 10.1371/journal.pone.0117458]
42. Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev 2011; 241: 260-268 [PMID: 21488902 DOI: 10.1111/j.1600-065X.2011.01018.x]
43. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787 [PMID: 18510923 DOI: 10.1016/j.cell.2008.05.009]
44. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 2457-2464 [PMID: 15781662 DOI: 10.1158/0008-5472.CAN-04-3232]
45. Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, Manns MP, Korangy F. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T- cell responses in patients with advanced HCC. J Immunother 2010; 33: 211-218 [PMID: 20139774 DOI: 10.1097/CJI.0b013e3181bb499f]
46. Thakur S, Singla A, Chawla Y, Rajwanshi A, Kalra N, Arora SK. Expansion of peripheral and intratumoral regulatory T- cells in hepatocellular carcinoma: a case-control study. Indian J Pathol Microbiol 2011; 54: 448-453 [PMID: 21934201 DOI: 10.4103/0377-4929.85073]
47. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902-911 [PMID: 17289884 DOI: 10.1158/1078-0432.CCR-06-2363]
48. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS. Increased regulatory T cells correlate with CD8 T- cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339 [PMID: 17570208 DOI: 10.1053/j. gastro.2007.03.102]
49. Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006; 214: 229-238 [PMID: 17100888 DOI: 10.1111/j.1600-065X.2006.00445.x]
50. Bergmann C, Wild CA, Narwan M, Lotfi R, Lang S, Brandau S. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells. Eur J Immunol 2011; 41: 3564-3573 [PMID: 21905023 DOI: 10.1002/eji.201141532]
51. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50: 980-989 [PMID: 19329213 DOI: 10.1016/j.jhep.2008.12.033]
52. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183: 4169-4175 [PMID: 19767566 DOI: 10.4049/jimmunol.0901017]
53. Yan J, Liu XL, Xiao G, Li NL, Deng YN, Han LZ, Yin LC, Ling LJ, Liu LX. Prevalence and clinical relevance of T- helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma. PLoS One 2014; 9: e96080 [PMID: 24867183 DOI: 10.1371/journal.pone.0096080]
54. Huang Y, Wang F, Wang Y, Zhu Z, Gao Y, Ma Z, Xu R, Du Z. Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29:851-859 [PMID: 24303990 DOI: 10.1111/jgh.12418]
55. Berzofsky JA, Terabe M. The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 2009; 9: 667-672 [PMID: 19689293]
56. Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N, Cerottini JC, Romero P, Porcelli SA, Macdonald HR, Speiser DE. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 2009; 182: 5140-5151 [PMID:19342695 DOI: 10.4049/jimmunol.0711086]
57. Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, Terris B, Yamagoe S, Colnot S, Viguier M, Perret C, Couty JP. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 2012; 122: 586-599 [PMID: 22251704 DOI: 10.1172/JCI43937]
58. Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, Yoon JH, Lee HS, Kim CY, Yi NJ, Suh KS, Lee KU, Chu IS, Roskams T, Thorgeirsson SS, Kim YJ. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 2056-2064 [PMID: 18381945 DOI: 10.1158/1078-0432. CCR-07-1473]
59. Ikeguchi M, Hirooka Y. Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie 2005; 28: 255-259 [PMID: 15867481 DOI: 10.1159/000084695]
60. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol 2001; 18: 257-264 [PMID: 11172590]
61. Yamaji K, Nabeshima S, Murata M, Chong Y, Furusyo N, Ikematsu H, Hayashi J. Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment. Cancer Immunol Immunother 2006; 55: 394-403 [PMID: 16041541 DOI: 10.1007/s00262-005-0005-x]
62. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2010; 32: 17-31 [PMID:20127093 DOI: 10.1007/s00281-009-0188-x]
63. Qin S, Ma S, Huang X, Lu D, Zhou Y, Jiang H. Th22 cells are associated with hepatocellular carcinoma development and progression. Chin J Cancer Res 2014; 26: 135-141 [PMID: 24826053 DOI: 10.3978/j.issn.1000-9604.2014.02.14]
64. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612 [PMID:16423985 DOI: 10.1158/0008-5472.CAN-05-4005]
65. Wang YY, Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI. Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J Chin Med Assoc 2003; 66: 593-598 [PMID: 14703276]
66. Morsi MI, Hussein AE, Mostafa M, El-Abd E, El-Moneim NA. Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci 2006; 63: 74-78 [PMID: 16871999]
67. Bortolami M, Venturi C, Giacomelli L, Scalerta R, Bacchetti S, Marino F, Floreani A, Lise M, Naccarato R, Farinati F. Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. Dig Liver Dis 2002; 34: 794-801 [PMID: 12546515]
68. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links Ann N Y Acad Sci 2009; 1155: 206-221 [PMID: 19250206 DOI: 10.1111/j.1749-6632.2009.03704.x]
69. Tanaka Y, Furuta T, Suzuki S, Orito E, Yeo AE, Hirashima N, Sugauchi F, Ueda R, Mizokami M. Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virusrelated hepatocellular carcinoma in Japan. J Infect Dis 2003; 187:1822-1825 [PMID: 12751042 DOI: 10.1086/375248]
70. Lee KA, Ki CS, Kim HJ, Sohn KM, Kim JW, Kang WK, Rhee JC, Song SY, Sohn TS. Novel interleukin 1beta polymorphism increased the risk of gastric cancer in a Korean population. J Gastroenterol 2004; 39: 429-433 [PMID: 15175940 DOI: 10.1007/s00535-003-1315-4]
71. Shiraki K, Yamanaka T, Inoue H, Kawakita T, Enokimura N, Okano H, Sugimoto K, Murata K, Nakano T. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int J Oncol 2005; 26: 1273-1281 [PMID: 15809718]
72. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, Grosse-Wilde H, Broelsch CE, Gerken G, Cicinnati VR. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 2004; 10: 7260-7269 [PMID: 15534100 DOI: 10.1158/1078-0432.CCR-04-0872]
73. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009; 124: 2766-2770 [PMID: 19267406 DOI: 10.1002/ijc.24281]
74. Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, D'Alessandro N, Montalto G. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963: 46-52 [PMID: 12095927]
75. Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH, Kim JK, Wang HJ, Cheong JY, Cho SW. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment. Cytokine 2015; 73: 245-252 [PMID: 25797190 DOI: 10.1016/j.cyto.2015.02.027]
76. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010; 11: 1014-1022 [PMID: 20935647 DOI: 10.1038/ni.1944]
77. Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K, Hubscher SG, Adams DH. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 1999; 30: 100-111 [PMID:10385645 DOI: 10.1002/hep.510300147]
78. Li W, Gomez E, Zhang Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J Exp Clin Cancer Res 2007; 26: 527-533 [PMID: 18365549]
79. Sutton A, Friand V, Brulé-Donneger S, Chaigneau T, Ziol M, Sainte-Catherine O, Poiré A, Saffar L, Kraemer M, Vassy J, Nahon P, Salzmann JL, Gattegno L, Charnaux N. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res 2007; 5: 21-33 [PMID: 17259344 DOI: 10.1158/1541-7786. MCR-06-0103]
80. Liu H, Pan Z, Li A, Fu S, Lei Y, Sun H, Wu M, Zhou W. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 2008; 5: 373-378 [PMID: 18954561 DOI: 10.1038/cmi.2008.46]
81. Schimanski CC, Bahre R, Gockel I, Müller A, Frerichs K, Hörner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, Schuler M, Achenbach T, Junginger T, Galle PR, Moehler M. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer 2006; 95: 210-217 [PMID: 16819541 DOI: 10.1038/sj.bjc.6603251]
82. Nahon P, Sutton A, Rufat P, Simon C, Trinchet JC, Gattegno L, Beaugrand M, Charnaux N. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 2008; 14:713-719 [PMID: 18205260]
83. Rubie C, Frick VO, Wagner M, Weber C, Kruse B, Kempf K, König J, Rau B, Schilling M. Chemokine expression in hepatocellular carcinoma versus colorectal liver metastases. World J Gastroenterol 2006; 12: 6627-6633 [PMID: 17075975]
84. Matsubara T, Ono T, Yamanoi A, Tachibana M, Nagasue N. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol 2007; 95: 241-249 [PMID: 17323338 DOI: 10.1002/jso.20642]
85. Liu Y, Poon RT, Feng X, Yu WC, Luk JM, Fan ST. Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma. Am J Gastroenterol 2004; 99: 1111-1121 [PMID: 15180734 DOI: 10.1111/j.1572-0241.2004.30265.x]
86. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, Zheng SS. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011; 6:e24671 [PMID: 21935436 DOI: 10.1371/journal.pone.0024671]
87. Chia CS, Ban K, Ithnin H, Singh H, Krishnan R, Mokhtar S, Malihan N, Seow HF. Expression of interleukin-18, interferongamma and interleukin-10 in hepatocellular carcinoma. ImmunolLett 2002; 84: 163-172 [PMID: 12413732]
88. Essand M, Loskog AS. Genetically engineered T cells for the treatment of cancer. J Intern Med 2013; 273: 166-181 [PMID:23198862 DOI: 10.1111/joim.12020]
89. Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tübingen approach: identification, selection, and validation of tumorassociated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004; 53: 187-195 [PMID: 14758508 DOI: 10.1007/s00262-003-0480-x]